🚀 VC round data is live in beta, check it out!
PROCEPT BioRobotics Valuation Multiples
Discover revenue and EBITDA valuation multiples for PROCEPT BioRobotics and similar public comparables like Haier Biomedical, Enovis, Axogen, Oxford Nanopore Technologies and more.
PROCEPT BioRobotics Overview
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Founded
2021
HQ
Employees
756
Website
Financials (LTM)
EV
$1B
PROCEPT BioRobotics Financials
PROCEPT BioRobotics reported last 12-month revenue of $331M and negative EBITDA of ($44M).
In the same LTM period, PROCEPT BioRobotics generated $213M in gross profit, ($44M) in EBITDA losses, and had net loss of ($93M).
Revenue (LTM)
PROCEPT BioRobotics P&L
In the most recent fiscal year, PROCEPT BioRobotics reported revenue of $308M and EBITDA of ($50M).
PROCEPT BioRobotics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $331M | XXX | $308M | XXX | XXX | XXX |
| Gross Profit | $213M | XXX | $196M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | ($44M) | XXX | ($50M) | XXX | XXX | XXX |
| EBITDA Margin | (13%) | XXX | (16%) | XXX | XXX | XXX |
| EBIT Margin | (31%) | XXX | (34%) | XXX | XXX | XXX |
| Net Profit | ($93M) | XXX | ($96M) | XXX | XXX | XXX |
| Net Margin | (28%) | XXX | (31%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PROCEPT BioRobotics Stock Performance
PROCEPT BioRobotics has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
PROCEPT BioRobotics' stock price is $26.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $-1.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPROCEPT BioRobotics Valuation Multiples
PROCEPT BioRobotics trades at 3.9x EV/Revenue multiple, and (29.6x) EV/EBITDA.
EV / Revenue (LTM)
PROCEPT BioRobotics Financial Valuation Multiples
As of April 7, 2026, PROCEPT BioRobotics has market cap of $1B and EV of $1B.
Equity research analysts estimate PROCEPT BioRobotics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PROCEPT BioRobotics has a P/E ratio of (16.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | (29.6x) | XXX | (25.7x) | XXX | XXX | XXX |
| EV/EBIT | (12.8x) | XXX | (12.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | 6.6x | XXX | XXX | XXX |
| P/E | (16.1x) | XXX | (15.7x) | XXX | XXX | XXX |
| EV/FCF | (34.8x) | XXX | (34.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PROCEPT BioRobotics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PROCEPT BioRobotics Margins & Growth Rates
PROCEPT BioRobotics' revenue in the last 12 month grew by 27%.
PROCEPT BioRobotics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
PROCEPT BioRobotics' rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PROCEPT BioRobotics' rule of X is 65% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PROCEPT BioRobotics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | (13%) | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Growth | (68%) | XXX | (49%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 97% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PROCEPT BioRobotics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Haier Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Enovis | XXX | XXX | XXX | XXX | XXX | XXX |
| Axogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford Nanopore Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Nolato | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PROCEPT BioRobotics M&A Activity
PROCEPT BioRobotics acquired XXX companies to date.
Last acquisition by PROCEPT BioRobotics was on XXXXXXXX, XXXXX. PROCEPT BioRobotics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PROCEPT BioRobotics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPROCEPT BioRobotics Investment Activity
PROCEPT BioRobotics invested in XXX companies to date.
PROCEPT BioRobotics made its latest investment on XXXXXXXX, XXXXX. PROCEPT BioRobotics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PROCEPT BioRobotics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PROCEPT BioRobotics
| When was PROCEPT BioRobotics founded? | PROCEPT BioRobotics was founded in 2021. |
| Where is PROCEPT BioRobotics headquartered? | PROCEPT BioRobotics is headquartered in United States. |
| How many employees does PROCEPT BioRobotics have? | As of today, PROCEPT BioRobotics has over 756 employees. |
| Who is the CEO of PROCEPT BioRobotics? | PROCEPT BioRobotics' CEO is Larry L. Wood. |
| Is PROCEPT BioRobotics publicly listed? | Yes, PROCEPT BioRobotics is a public company listed on Nasdaq. |
| What is the stock symbol of PROCEPT BioRobotics? | PROCEPT BioRobotics trades under PRCT ticker. |
| When did PROCEPT BioRobotics go public? | PROCEPT BioRobotics went public in 2021. |
| Who are competitors of PROCEPT BioRobotics? | PROCEPT BioRobotics main competitors are Haier Biomedical, Enovis, Axogen, Oxford Nanopore Technologies. |
| What is the current market cap of PROCEPT BioRobotics? | PROCEPT BioRobotics' current market cap is $1B. |
| What is the current revenue of PROCEPT BioRobotics? | PROCEPT BioRobotics' last 12 months revenue is $331M. |
| What is the current revenue growth of PROCEPT BioRobotics? | PROCEPT BioRobotics revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of PROCEPT BioRobotics? | Current revenue multiple of PROCEPT BioRobotics is 3.9x. |
| Is PROCEPT BioRobotics profitable? | No, PROCEPT BioRobotics is not profitable. |
| What is the current EBITDA of PROCEPT BioRobotics? | PROCEPT BioRobotics has negative EBITDA and is not profitable. |
| What is PROCEPT BioRobotics' EBITDA margin? | PROCEPT BioRobotics' last 12 months EBITDA margin is (13%). |
| What is the current EV/EBITDA multiple of PROCEPT BioRobotics? | Current EBITDA multiple of PROCEPT BioRobotics is (29.6x). |
| What is the current FCF of PROCEPT BioRobotics? | PROCEPT BioRobotics' last 12 months FCF is ($37M). |
| What is PROCEPT BioRobotics' FCF margin? | PROCEPT BioRobotics' last 12 months FCF margin is (11%). |
| What is the current EV/FCF multiple of PROCEPT BioRobotics? | Current FCF multiple of PROCEPT BioRobotics is (34.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.